JP2009515901A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515901A5 JP2009515901A5 JP2008540275A JP2008540275A JP2009515901A5 JP 2009515901 A5 JP2009515901 A5 JP 2009515901A5 JP 2008540275 A JP2008540275 A JP 2008540275A JP 2008540275 A JP2008540275 A JP 2008540275A JP 2009515901 A5 JP2009515901 A5 JP 2009515901A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- treatment
- inhibitor
- patient
- inhibitor according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 8
- 229940124302 mTOR inhibitor Drugs 0.000 claims 7
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960001302 ridaforolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73676305P | 2005-11-14 | 2005-11-14 | |
| US60/736,763 | 2005-11-14 | ||
| PCT/US2006/044146 WO2007059106A2 (en) | 2005-11-14 | 2006-11-14 | Administration of mntor inhibitor to treat patients with cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191029A Division JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515901A JP2009515901A (ja) | 2009-04-16 |
| JP2009515901A5 true JP2009515901A5 (enExample) | 2010-01-21 |
| JP5709354B2 JP5709354B2 (ja) | 2015-04-30 |
Family
ID=38049229
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540275A Expired - Fee Related JP5709354B2 (ja) | 2005-11-14 | 2006-11-14 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
| JP2013191029A Pending JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013191029A Pending JP2014012721A (ja) | 2005-11-14 | 2013-09-13 | ｍＴＯＲ阻害剤投与によるがん患者の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070185150A1 (enExample) |
| EP (2) | EP2662082A1 (enExample) |
| JP (2) | JP5709354B2 (enExample) |
| CN (2) | CN101360495B (enExample) |
| AU (1) | AU2006315512B2 (enExample) |
| CA (1) | CA2629714A1 (enExample) |
| EA (1) | EA015922B1 (enExample) |
| IL (1) | IL191356A0 (enExample) |
| WO (1) | WO2007059106A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008016633A2 (en) * | 2006-08-02 | 2008-02-07 | Ariad Gene Therapeutics, Inc. | Combination therapy |
| JP2010509400A (ja) * | 2006-11-14 | 2010-03-25 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 経口処方組成物 |
| US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
| EP2365802B1 (en) * | 2008-11-11 | 2017-08-02 | The Board of Regents,The University of Texas System | Microcapsules of rapamycin and use for treating cancer |
| AU2010236825A1 (en) | 2009-04-16 | 2011-09-15 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| US8911766B2 (en) * | 2009-06-26 | 2014-12-16 | Abbott Cardiovascular Systems Inc. | Drug delivery compositions including nanoshells for triggered drug release |
| WO2011024168A2 (en) * | 2009-08-26 | 2011-03-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd | Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| US9283211B1 (en) | 2009-11-11 | 2016-03-15 | Rapamycin Holdings, Llc | Oral rapamycin preparation and use for stomatitis |
| MX2012011912A (es) * | 2010-04-13 | 2012-11-16 | Novartis Ag | Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer. |
| JP2012061053A (ja) | 2010-09-14 | 2012-03-29 | Yuuki Kitaoka | 投薬装置、投薬装置の作動方法及び投薬方法 |
| AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| UA110961C2 (uk) * | 2011-04-25 | 2016-03-10 | Новартіс Аг | КОМБІНАЦІЯ ІНГІБІТОРУ ФОСФАТИДИЛІНОЗИТ-3-КІНАЗИ (PI3K) І ІНГІБІТОРУ mTOR |
| MX363034B (es) * | 2011-12-02 | 2019-03-06 | Signal Pharm Llc | Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il)piridin- 3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b]pi razin-2(1h)-ona, una forma solida de las mismas y metodos de su uso. |
| HK1202435A1 (en) | 2012-05-16 | 2015-10-02 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
| EP2919759A4 (en) | 2012-11-14 | 2016-07-20 | Ohio State Innovation Foundation | MATERIALS AND METHODS FOR THE TREATMENT OF GLIOBLASTOMES |
| DK2968281T3 (da) | 2013-03-13 | 2020-11-02 | Univ Texas | Mtor-hæmmere til forebyggelse af vækst af tarmpolyp |
| CN104721158B (zh) * | 2013-12-24 | 2018-01-30 | 正大天晴药业集团股份有限公司 | 一种稳定的依维莫司片剂 |
| AU2014373683B2 (en) | 2013-12-31 | 2020-05-07 | Rapamycin Holdings, Llc | Oral rapamycin nanoparticle preparations and use |
| US9700544B2 (en) | 2013-12-31 | 2017-07-11 | Neal K Vail | Oral rapamycin nanoparticle preparations |
| CN106166296A (zh) * | 2016-07-01 | 2016-11-30 | 江南大学 | 一种辅助雷帕霉素治疗多种肿瘤的药物组合物 |
| CN107714719A (zh) * | 2017-11-08 | 2018-02-23 | 上海市第妇婴保健院 | 雷帕霉素在制备治疗白细胞介素‑27低表达子宫内膜癌的药物中的应用 |
| EP4108242B1 (en) * | 2020-02-21 | 2025-07-09 | Korea Advanced Institute of Science and Technology | Pharmaceutical composition for preventing or treating cancer, containing mtor-signaling inhibitor as active ingredient |
| CN114767867A (zh) * | 2021-12-22 | 2022-07-22 | 中山大学孙逸仙纪念医院 | 一种用于治疗cdk4/6抑制剂耐药后的乳腺癌的药物组合物及其应用 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
| US5378696A (en) * | 1990-09-19 | 1995-01-03 | American Home Products Corporation | Rapamycin esters |
| US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
| US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
| US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
| ES2084940T3 (es) | 1991-06-18 | 1996-05-16 | American Home Prod | Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. |
| ZA924953B (en) | 1991-07-25 | 1993-04-28 | Univ Louisville Res Found | Method of treating ocular inflammation |
| US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
| US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
| US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
| US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
| ES2295093T3 (es) | 1993-04-23 | 2008-04-16 | Wyeth | Conjugados y anticuerpos de rapamicina. |
| CH686761A5 (de) | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| ATE198041T1 (de) | 1993-09-28 | 2000-12-15 | Scherer Gmbh R P | Herstellung von weichgelatinekapseln |
| US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
| US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
| FR2736550B1 (fr) | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| GB0000482D0 (en) | 2000-01-11 | 2000-03-01 | Norton Healthcare Ltd | Enteric coated pharmaceutical formulation |
| LT2762140T (lt) | 2001-02-19 | 2017-06-26 | Novartis Ag | Solidinių smegenų navikų gydymas rapamicino dariniu |
| CN1309421C (zh) * | 2001-04-06 | 2007-04-11 | 惠氏公司 | 诸如雷帕霉素和吉西他滨或氟尿嘧啶的抗肿瘤联合 |
| JP4416501B2 (ja) | 2001-05-30 | 2010-02-17 | ノバルティス アクチエンゲゼルシャフト | ２−｛［ｎ−（２−アミノ−３−（ヘテロアリールまたはアリール）プロピオニル）−アミノアシル］−アミノ｝−アルキルボロン酸誘導体 |
| CN101717410B (zh) | 2002-02-01 | 2015-04-29 | 阿里亚德医药股份有限公司 | 含磷化合物及其应用 |
| JP2006506353A (ja) | 2002-09-17 | 2006-02-23 | ワイス | 経口処方 |
| SG135193A1 (en) * | 2003-08-18 | 2007-09-28 | Pfizer Prod Inc | Dosing schedule for erbb2 anticancer agents |
| GB0327840D0 (en) * | 2003-12-01 | 2003-12-31 | Novartis Ag | Organic compounds |
| BRPI0418373A (pt) | 2004-01-08 | 2007-05-22 | Wyeth Corp | composição farmacêutica, unidade de dosagem de cci-779 oral, método de fornecimento de cci-779 a um paciente, e, uso de cci-779 micronizado |
| US7405497B2 (en) | 2004-04-13 | 2008-07-29 | Electrovaya Inc. | Integrated power supply system |
| MX2007003790A (es) * | 2004-09-30 | 2007-05-24 | Ariad Gene Therapeutics Inc | Metodo de tratamiento. |
| US20060183766A1 (en) | 2005-02-15 | 2006-08-17 | Wyeth | Orally bioavailable CCI-779 formulations |
| GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
| DE102005017313A1 (de) | 2005-04-14 | 2006-10-19 | Volkswagen Ag | Verfahren zur Darstellung von Informationen in einem Verkehrsmittel und Kombiinstrument für ein Kraftfahrzeug |
| PE20071042A1 (es) * | 2005-11-04 | 2007-10-12 | Wyeth Corp | Producto farmaceutico que comprende temsirolimus y malato de sunitinib |
-
2006
- 2006-11-14 CN CN2006800510347A patent/CN101360495B/zh not_active Expired - Fee Related
- 2006-11-14 CA CA002629714A patent/CA2629714A1/en not_active Abandoned
- 2006-11-14 EP EP13179744.1A patent/EP2662082A1/en not_active Withdrawn
- 2006-11-14 EP EP06844354A patent/EP1962839A4/en not_active Withdrawn
- 2006-11-14 JP JP2008540275A patent/JP5709354B2/ja not_active Expired - Fee Related
- 2006-11-14 CN CN2012100014166A patent/CN102579467A/zh active Pending
- 2006-11-14 EA EA200801309A patent/EA015922B1/ru not_active IP Right Cessation
- 2006-11-14 WO PCT/US2006/044146 patent/WO2007059106A2/en not_active Ceased
- 2006-11-14 AU AU2006315512A patent/AU2006315512B2/en not_active Ceased
- 2006-11-14 US US11/598,850 patent/US20070185150A1/en not_active Abandoned
-
2008
- 2008-05-12 IL IL191356A patent/IL191356A0/en unknown
-
2013
- 2013-09-13 JP JP2013191029A patent/JP2014012721A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515901A5 (enExample) | ||
| JP2009539769A5 (enExample) | ||
| IL273765A (en) | Combinations and forms of administration of therapeutic agents and combined treatment | |
| JP2014040437A5 (enExample) | ||
| JP2008530248A5 (enExample) | ||
| JP2009545601A5 (enExample) | ||
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| JP2009506054A5 (enExample) | ||
| JP2013518124A5 (enExample) | ||
| JP2015527374A5 (enExample) | ||
| JP2009536956A5 (enExample) | ||
| JP2005530735A5 (enExample) | ||
| RU2012108144A (ru) | Противораковая терапия, направленная против раковых стволовых клеток и форм рака, устойчивых к лечению лекарственными препаратами | |
| JP2008517991A5 (enExample) | ||
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| JP2015510945A5 (enExample) | ||
| JP2011500650A5 (enExample) | ||
| RU2009116629A (ru) | Азитромицин для лечения узелковых угрей | |
| JP2007538066A5 (enExample) | ||
| Kalavrezos et al. | Mouth cancer for clinicians part 12: cancer treatment (chemotherapy and targeted therapy) | |
| JP2010519274A5 (enExample) | ||
| CN104146999A (zh) | 冬凌草甲素和多烯紫杉醇减毒增效抗肿瘤药物组合物及其应用 | |
| CY1112814T1 (el) | Αντιμετωπιση ανθεκτικων στα φαρμακα ογκων | |
| HK1133829A (en) | Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer | |
| Lin et al. | Tolerabil ity of Oxal ipltin2based Adjuvant Chemotherapy in Colorectal Cancer Patients |